Edgewise Therapeutics Inc
NASDAQ:EWTX

Watchlist Manager
Edgewise Therapeutics Inc Logo
Edgewise Therapeutics Inc
NASDAQ:EWTX
Watchlist
Price: 23.75 USD -4.29% Market Closed
Market Cap: 2.5B USD

Net Margin
Edgewise Therapeutics Inc

0%
Current
0%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-157.2m
/
Revenue
0

Net Margin Across Competitors

No Stocks Found

Edgewise Therapeutics Inc
Glance View

Market Cap
2.5B USD
Industry
Pharmaceuticals

Edgewise Therapeutics Inc. is a biopharmaceutical company that has carved its niche by focusing intently on developing treatments for rare muscle disorders. Founded with the vision of addressing the unmet needs within the realm of muscular dystrophies and other rare myopathies, Edgewise aims to combat these challenges through precision medicine. Its unique approach lies in leveraging its proprietary drug discovery platform to identify and develop small molecule therapies that target the underlying causes of these muscle disorders. By honing in on the mechanistic roots of muscle dysfunction, Edgewise aspires to improve the quality of life for patients who often have limited treatment options available. The company generates revenue primarily through the successful development and potential commercialization of its therapies. As with many biopharmaceutical entities, the cornerstone of Edgewise's financial strategy is to push its drug candidates through the clinical trial phases efficiently, demonstrating safety and efficacy to obtain regulatory approval. Partnerships, collaborations, and licensing agreements often play a critical role in supplementing its revenue stream, enabling Edgewise to leverage additional resources and expertise. By addressing the therapeutic gaps in rare muscle disorders with promising candidates that have the potential to be first-in-class or best-in-class treatments, Edgewise Therapeutics strategically positions itself to create significant value for its patients and stakeholders alike.

EWTX Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-157.2m
/
Revenue
0
What is the Net Margin of Edgewise Therapeutics Inc?

Based on Edgewise Therapeutics Inc's most recent financial statements, the company has Net Margin of 0%.

Back to Top